CAS: 452-06-2; 7H-Purin-2-Amine

该化合物是一种纯衍生物,配有化学配方C5H6N4,其特点是在纯环的2位置上有一个氨基质组,它是在水和极有机溶剂中溶解的白到光黄色晶状固体,以其作为核糖基类比的作用而著称,可替代核酸中的亚丁,从而导致DNA复制过程中的突变.由于该化合物在结构上与丹因相似,2-氨基质可以干扰正常基配对,使其成为分子生物学和遗传学研究DNA过程的宝贵工具.此外,该化合物在癌症研究中和植物生长调节器中的潜在应用受到了调查.该化合物在实验室环境中处理时,应表现出中度的毒性和安全防范作用.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

4-morpholinecarboxaldehyde pyrimidine-2,4,5-triamine formamide 2-(methylthio)-9H-purine 1,3-dihydro-2H-purin-2-one H-purine2-fluoro-7(9)H-purine 2-amino-9-benzyl-9H-purine methyl 3-(2-amino-9H-purin-9-yl)propionate

合成工艺路线路线简述

  • 合成目标产物 2-Aminopurine 主要起始原料 6-Chloroguanine
  • (文献来源)合成步骤主要原料 6-Chloroguanine
2-[(2-Aminocyclopentanecarbonyl)Amino]-2-[6-(2-Aminopurin-9-yl)-4-(1,2-Dihydroxyethyl)-4,5-Dihydroxyoxan-2-Yl]Acetic Acid置于三氟乙酸体系中,用48%的收率获得产物2-氨基嘌呤
参考文献:阿米普霉素的结构,一种具有新的分支糖部分的核苷抗生素
标题:阿米普霉素的结构,一种具有新的分支糖部分的核苷抗生素
摘要:化学鉴定阿米霉素的结构为.
DOI:10.1016/s0040-4039(00)87080-X

专利信息


专利号:US-9884885-B2
优先权日:2009-05-18
标题:Synthesis of labile base protected-modified deoxy and modified ribo nucleosides, corresponding phosphoramidites and supports and their use in high purity oligonucleotide synthesis
发明人:SRIVASTAVA SURESH C; SRIVASTAVA NAVEEN P
权利人:SRIVASTAVA SURESH C; SRIVASTAVA NAVEEN P; CHEMGENES CORP
摘要:This invention relates to novel method of synthesis of RNA utilizing N-2-acetyl protected guanine as nucleoside base, nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N-acetyl protected guanine as nucleoside base protecting group, which is significantly faster base labile protecting group, yet significantly more stable than commonly utilized-2-isobutyryl guanosine is a novel approach to obtain highest purity oligonucleotides. This approach is designed to lead to very high purity and very clean oligonucleotide, after efficient removal of the protecting groups, including acetyl group from guanine and to produce high purity therapeutic grade DNA oligonucleotides, RNA oligonucleotides, diagnostic DNA, diagnostic RNA for microarray platform. The deprotection of acetyl protecting groups of the natural deoxy and ribonucleosides occurs under substantially reduced time in contact with mild deprotection conditions such as mild bases, secondary amines for removal of such groups under such conditions would allows synthesis of various DNA and RNA of highest purity for diagnostics and therapeutic application. This approach is designed to lead to high purity large scale therapeutic grade oligonucleotide chimeras which consist of fluoro sugar modification in conjunction with deoxy nucleosides, ribonucleosides, modified base and modified sugar nucleosides. This approach is further designed to use acetyl guanine protecting group when other bases are sensitive nucleoside, and for use in oligo peptide synthesis and for support bound oligo nucleotides.

专利号:US-8981076-B2
优先权日:2008-11-29
标 题 :Synthesis of N-FMOC protected deoxy nucleosides, ribo nucleosides, modified deoxy and ribo nucleosides, and phosphoramidites, and their use in oligonucleotide synthesis
发明人:SRIVASTAVA SURESH C; SRIVASTAVA NAVEEN P
权利人:SRIVASTAVA SURESH C; SRIVASTAVA NAVEEN P; CHEMGENES CORP
摘要:This invention relates to synthesis of novel -N-FMOC protected nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N-FMOC as nucleoside base protecting group, which is highly base labile protecting group is a novel approach to obtain highest purity oligonucleotides. This approach is designed to lead to very high purity and very clean oligonucleotide, after efficient removal of the protecting groups and to produce high purity therapeutic grade DNA oligonucleotides, RNA oligonucleotides, diagnostic DNA, diagnostic RNA for microarray platform. The deprotection of FMOC protecting groups of the natural deoxy and ribonucleosides occurs under very mild deprotection conditions such as mild bases, secondary and tertiary amines for removal of such groups under such conditions would allows synthesis of various DNA and RNA of highest purity for diagnostics and therapeutic application. This approach is further designed to use FMOC protecting group on various base sensitive nucleoside, and for use in oligo peptide synthesis and for support bound oligo nucleotides. DNA oligonucleotides containing 3′-end dA at the 3′-terminal will be produced using the FMOC-dA-supports would lead to much reduced M−1 deletion sequences, and thereby high purity.

专利号:US-8618279-B2
优先权日:2009-01-15
标 题 :Synthesis of 2′,3′— and 3′,5′—cyclic phosphate mono-and oligonucleotides
发明人:LAIKHTER ANDREI; SRIVASTAVA SURESH CHANDRA; SRIVASTAVA NAVEEN
权利人:LAIKHTER ANDREI; SRIVASTAVA SURESH CHANDRA; SRIVASTAVA NAVEEN; CHEMGENES CORP
摘要:The invention provides a novel method for the chemical synthesis of 2′,3′-cyclic phosphate and phosphorothioate of mono and terminated oligonucleotides synthesis. The invention also provides a novel method of for the chemical synthesis of 2′,3′- and 3′,5′-cyclic phosphate and phosphorothioate mononucleotide nucleotides. The process is based on quick and efficient cyclization of phosphoramidate moiety and neighboring hydroxyl group. The present invention is directed towards the synthesis of high purity DNA and RNAs, specifically to introduce cyclic phosphate at 3′-end of oligonucleotides. Such DNA and RNA's have extensive application in therapeutics, diagnostics, drug design, and selective inhibition of an RNA sequence within cellular environment, in pre-tRNA cleavage and in ribozyme ligation. The 2′,3′-cyclic phosphate nucleosides are involved in a vast number of applications in molecular biology in general and mammalian cells in particular. The invention also envisions providing kits comprising at least one composition disclosed in the present invention.

专利号:US-5977301-A
优先权日:1992-09-24
标题 :Synthesis of N-substituted oligomers
发明人:ZUCKERMAN RONALD N; KERR JANICE M; KENT STEPHEN B H; MOOS WALTER H; SIMON REYNA J; GOFF DANE A
权利人:CHIRON CORP
摘要:A solid-phase method for the synthesis of N-substituted oligomers, such as poly (N-substituted glycines) (referred to herein as poly NSGs) is used to obtain oligomers, such as poly NSGs of potential therapeutic interest which poly NSGs can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two 'sub-monomers' directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a resin-bound alpha -haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability.

专利号:EP-0671928-B1
优先权日:1992-09-24
标题 :Synthesis of n-substituted oligomers
发明人:ZUCKERMANN RONALD N; KERR JANICE M; KENT STEPHEN BRIAN HENRY; MOOS WALTER H; SIMON REYNA J; GOFF DANE A
权利人:CHIRON CORP
摘要:Poly N-substituted Glycines (poly NSGs), wherein the substituents bear purine or pyrimidine bases (R<9>) every second glycine: In addition, a solid phase method for the synthesis of N-substituted oligomers of more general structures is disclosed.The poly NSGs obtainable by this method can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two 'sub-monomers' directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a resin-bound alpha -haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using the automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability.

专利号:US-5789577-A
优先权日:1994-12-30
标 题 :Method for the controlled synthesis of polynucleotide mixtures which encode desired mixtures of peptides
发明人:GEYSEN H MARIO
权利人:CHIRON CORP
摘要:A method to obtain selected individual polynucleotides or mixtures thereof each of which encodes a peptide and at least one polynucleotide of the mixture encodes a peptide having a target property. The polynucleotides of the invention present in the mixture in detectable, retrievable, and clonable amounts are expressed in a host organism for screening for the target activity. The invention features the ability to synthesize controlled random polynucleotides to produce a predetermined mixture of polynucleotides and to avoid synthesis of a stop codon by adjusting the proportions into which the synthesis pool is subdivided and by adjusting the proportions of activated nucleotides added at each coupling step. A polynucleotide encoding a peptide having a target property can be selected and sequenced to deduce the amino acid sequence of the peptide.
上海亚兴生物医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.isotopemall.com
企业联系电话:021-58956006,021-58950017👤
📞上海亚兴生物医药科技有限公司 ⚠️参考联系方式
联系人:段经理
电话:021-58956006,021-58950017
手机:15800617331
传真:021-58956100
邮箱:sales@langchem.com
通信地址: 上海川沙新镇妙镜路1111弄恒越生活广场5号楼303室
邮编: 201204
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

地址:上海川沙新镇妙镜路1111弄恒越生活广场5号楼303室
⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
苏州市尤利特生物医药科技有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.unite-chem.com
电话: 0512-62575075👤
📞苏州市尤利特生物医药科技有限公司 ⚠️参考联系方式

销售电话:0512-62575075
邮箱:sales@unite-chem.com
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Brovarets' OO, Voiteshenko IS, Hovorun DM. Physico-chemical profiles of the wobble ↔ Watson-Crick G*·2AP(w) ↔ G·2AP(WC) and A·2AP(w) ↔ A*·2AP(WC) tautomerisations: a QM/QTAIM comprehensive survey. Phys Chem Chem Phys. 2017 Dec 20;20(1):623-636. doi: 10.1039/c7cp05139e. doi: 10.1016/j.bmc.2017.11.020. Epub 2017 Nov 11.
3: Zargarian L, Ben Imeddourene A, Gavvala K, Barthes NPF, Michel BY, Kenfack CA, Morellet N, René B, Fossé P, Burger A, Mély Y, Mauffret O. Structural and Dynamical Impact of a Universal Fluorescent Nucleoside Analogue Inserted Into a DNA Duplex. J Phys Chem B. 2017 Dec 21;121(50):11249-11261. doi: 10.1021/acs.jpcb.7b08825. Epub 2017 Dec 12. doi: 10.1016/j.talanta.2017.10.023. Epub 2017 Oct 16. doi: 10.1021/jacs.7b08755. Epub 2017 Nov 22. doi: 10.1039/c7mb00457e. doi: 10.1039/c7ob02001e. doi: 10.3791/56221. doi: 10.1021/acssensors.7b00313. Epub 2017 Oct 9. doi: 10.1007/978-1-4939-7240-1_19. doi: 10.1021/acs.analchem.7b02451. Epub 2017 Sep 21. doi: 10.1016/j.aca.2017.06.026. Epub 2017 Jun 20. doi: 10.1039/c7ob01709j. doi: 10.1021/acs.orglett.7b02273. Epub 2017 Aug 2. doi: 10.1638/2016-0063R.1. doi: 10.1002/cbic.201700272. Epub 2017 Aug 22. doi: 10.1016/j.talanta.2017.06.028. Epub 2017 Jun 13. doi: 10.1021/acs.jpcc.6b08086. Epub 2016 Nov 23.
19: Smith DA, McKenzie G, Jones AC, Smith T. Analysis of TCSPC data: a comparative evaluation of deterministic and probabilistic approaches. Methods Appl Fluoresc. 2017 Jul 18. doi: 10.1088/2050-6120/aa8055. [Epub ahead of print] Folding of the silver aptamer in a DNAzyme probed by 2-aminopurine fluorescence. Biochimie. 2017 Jul 12. pii: S0300-9084(17)30172-4. doi: 10.1016/j.biochi.2017.07.001. [Epub ahead of print]

合成参考文献


参考文献:10.1089/nat.2011.0296
摘要:Chang CI, Lee TY, Dua P, Kim S, Li CJ, Lee DK. Long double-stranded RNA-mediated RNA interference and immunostimulation: long interfering double-stranded RNA as a potent anticancer therapeutics. Nucleic Acid Ther. 2011 Jun;21(3):149–55. doi: 10.1089/nat.2011.0296.
参考文献:10.1021/jm200650j
摘要:Murakami E, Bao H, Mosley RT, Du J, Sofia MJ, Furman PA. Adenosine Deaminase-like Protein 1 (ADAL1): Characterization and Substrate Specificity in the Hydrolysis of N6- or O6-Substituted Purine or 2-Aminopurine Nucleoside Monophosphates. J. Med. Chem. 2011 Jul 22;54(16):5902–14. doi: 10.1021/jm200650j.
参考文献:10.1007/82_2011_144
摘要:Goodman RA, Macbeth MR, Beal PA. ADAR proteins: structure and catalytic mechanism. Curr Top Microbiol Immunol. 2012;353():1–33. doi: 10.1007/82_2011_144.
参考文献:10.1261/rna.2592411
摘要:Harris KA, Jones V, Bilbille Y, Swairjo MA, Agris PF. YrdC exhibits properties expected of a subunit for a tRNA threonylcarbamoyl transferase. RNA. 2011 Sep;17(9):1678–87.
参考文献:10.1086/498521
摘要:Aoki FY, Tyring S, Diaz-Mitoma F, Gross G, Gao J, Hamed K. Single-day, patient-initiated famciclovir therapy for recurrent genital herpes: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2006 Jan 01;42(1):8–13. doi: 10.1086/498521.
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知